[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363793-105":59,"doc-detail-363793-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","survival-prediction-in-patients-with-epidermal-growth-factor-receptor-mutated-non-small-cell-lung-cancer-with-bone-metastases-receiving-icotinib-therapy-a-retrospective-observational-study","Survival Prediction in Patients With Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer With Bone Metastases Receiving Icotinib Therapy - A Retrospective Observational Study","","Clinical prediction models for response to EGFR-TKI therapy in advanced non-small cell lung cancer with bone metastasis and EGFR mutations remain limited. This retrospective observational study evaluated predictors of response to icotinib in patients with EGFR-mutated NSCLC and bone metastases treated at Wuhan Union Hospital. Independent predictors of progression-free survival were determined using LASSO and multivariate Cox regression, and a prognostic nomogram was validated via ROC, DCA, and calibration.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/survival-prediction-in-patients-with-epidermal-growth-factor-receptor-mutated-non-small-cell-lung-cancer-with-bone-metastases-receiving-icotinib-therapy-a-retrospective-observational-study/363793/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/survival-prediction-in-patients-with-epidermal-growth-factor-receptor-mutated-non-small-cell-lung-cancer-with-bone-metastases-receiving-icotinib-therapy-a-retrospective-observational-study/363793.png","ImageObject",300,407,{"name":92,"@type":93},"Anna Hans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What patient population and therapy does the study analyze?","Question",{"text":112,"@type":113},"The study retrospectively analyzes patients with EGFR-mutated non-small cell lung cancer with bone metastases treated with icotinib at Wuhan Union Hospital.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which factors were identified as independent predictors of progression-free survival?",{"text":117,"@type":113},"In the overall cohort, bone metastases status was an independent predictor of PFS. In the bone metastasis subgroup, albumin, lactate dehydrogenase (LDH), and the platelet–lymphocyte ratio (PLR) were independently associated with PFS.",{"name":119,"@type":110,"acceptedAnswer":120},"How was the prognostic nomogram validated?",{"text":121,"@type":113},"The nomogram’s effectiveness was assessed using receiver operating characteristic (ROC) curves, decision curve analysis (DCA), and calibration curves to evaluate performance and clinical relevance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363793,1790640715,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909892332657,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Survival Prediction in Patients With Epidermal Growth Factor  \nReceptor-Mutated Non-small Cell Lung Cancer With Bone Metastases Receiving Icotinib Therapy: A Retrospective Observational Study  \nTechnology in Cancer Research & Treatment Volume 25: 1–15 © The Author(s) 2026 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)  \n[DOI: 10.1177/15330338261456855](DOI: 10.1177/15330338261456855)  \n[journals.sagepub.com/home/tct](journals.sagepub.com/home/tct)  \nYanling Ma1,2,3, Hui Xia1,2,3, Xueyun Tan1,2,3, Siwei Song1,2,3, Minglei Li1,2,3, Juanjuan Xu1,2,3, Feng Wu1,2,3, Yaqi Cao1,2,3, Mengjia Yi1,2,3, Sufei Wang1,2,3, and Yang Jin1,2,3  \nAbstract  \nIntroduction: Clinical prediction models for response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung cancer (NSCLC) with bone metastasis (BoM) and EGFR mutations are lacking. This study evaluated predictors of response to the EGFR-TKI icotinib in patients with NSCLC and BoM. Methods: We retrospectively analysed patients with EGFR-mutated NSCLC and BoM treated with icotinib at Wuhan Union Hospital. Least absolute shrinkage and selection operator and multivariate Cox regression analyses identified independent predictors of progression-free survival (PFS). A prognostic nomogram was developed, and its effectiveness was assessed using receiver operating characteristic (ROC) curves, a decision curve analysis (DCA), and calibration curves. Results: Among 194 patients (106 with and 88 without BoM), median PFS in the BoM group was 9.8 months, with a 35.8% overall response rate, and 66.0% disease control rate. In univariate and multivariate Cox regression analyses, BoM was an independent predictor of PFS in the overall cohort (hazard ratio [HR], 2.12; 95% confidence interval [CI], 1.34–3.07; P \u003C 0.001). In the BoM subgroup, albumin (HR: 0.36; 95% CI: 0.21–0.62; P \u003C 0.001), lactate dehydrogenase (LDH) (HR: 1.99; 95% CI: 1.21–3.28; P = 0.007), and the platelet– lymphocyte ratio (PLR) (HR: 1.85; 95% CI: 1.05–3.25; P = 0.033) were independently associated with PFS. A nomogram predicting 3-, 6-, and 12-month PFS achieved time-dependent areas under the ROC curve of 0.765, 0.743, and 0.724, respectively. Calibration plots and DCA demonstrated acceptable performance and potential clinical relevance. Conclusions: Albumin, LDH, and PLR predict PFS in EGFR-mutated NSCLC with BoM treated with icotinib. The proposed nomogram may assist in preliminary risk stratification in this specific population.  \n1Department of Respiratory and Critical Care Medicine, Hubei Province Clinical Research Center for Major Respiratory Diseases, NHC Key Laboratory of Pulmonary Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China  \n2Hubei Province Key Laboratory of Biological Targeted Therapy, MOE Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China  \n3Hubei Province Engineering Research Center for Tumor-Targeted Biochemotherapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China  \nCorresponding authors:  \nYang Jin, Department of Respiratory and Critical Care Medicine, Hubei Province Clinical Research Center for Major Respiratory Diseases, NHC Key Laboratory of Pulmonary Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China. [Email:](Email: whuhjy@126.com)[ whuhjy@126.com](Email: whuhjy@126.com)  \nSufei Wang, Department of Respiratory and Critical Care Medicine, Hubei Province Clinical Research Center for Major Respiratory Diseases, NHC Key Laboratory of Pulmonary Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China. [Email:](Email: wangsufei0@163.com)[ wangsufei0@163.c","cbCaiabC3lh7UhYc","https://ap.wps.com/l/cbCaiabC3lh7UhYc","pdf",2687507,15,"English","# Abstract\n## Introduction\n## Methods\n## Results\n## Conclusions\n## Keywords","[{\"question\":\"What patient population and therapy does the study analyze?\",\"answer\":\"The study retrospectively analyzes patients with EGFR-mutated non-small cell lung cancer with bone metastases treated with icotinib at Wuhan Union Hospital.\"},{\"question\":\"Which factors were identified as independent predictors of progression-free survival?\",\"answer\":\"In the overall cohort, bone metastases status was an independent predictor of PFS. In the bone metastasis subgroup, albumin, lactate dehydrogenase (LDH), and the platelet–lymphocyte ratio (PLR) were independently associated with PFS.\"},{\"question\":\"How was the prognostic nomogram validated?\",\"answer\":\"The nomogram’s effectiveness was assessed using receiver operating characteristic (ROC) curves, decision curve analysis (DCA), and calibration curves to evaluate performance and clinical relevance.\"}]","Survival Prediction in Patients With Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer With Bone Metastases Receiving Icotinib Therapy - A Retrospective Observational Study | PDF",1790153185,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/75bd01ea4edfd33ccbda5e1b3508b92a.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dfcfb57a937e539891c8c143b138df21.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11bb76e0156c39ac2b161d7df7ba1695.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2c553a7907e1d4204546e653fe96ee10.webp",980,1306]